Marta Zielinska

Dr. Marta Zielinska

Department of Biochemistry, Medical University of Lodz, Lodz, Poland

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2020 in Current Treatment Options in Oncology
Verified
Journal Article
Open access
PDF file
ASAdrian Szczepaniak
Adrian Szczepaniak
JFJakub Fichna
Jakub Fichna
Marta ZielinskaMarta Zielinska
Marta Zielinska
Opinion statement: So far, opioids have been successfully used to reduce cancer pain in patients in order to improve their quality of life. However, the use of opioids leads to numerous side effects such as constipation, drowsiness, nausea, itching, increased sweating and hormonal changes. In this review, we described the action of opioids in several molecular pathways significant for maintenance of the intestinal homeostasis including the impact on the intestinal epithelium integrity, changes in microbiome composition, modulation of the immune system or induction of apoptosis and inhibition of angiogenesis. We summed up the role of individual opioids in the processes involved in the growth and development of cancer and elucidated if targeting opioid receptors may constitute novel therapeutic option in colon cancer.

1 January 2021 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Closed access
MŚMikołaj Świerczyński
Mikołaj Świerczyński
ASAgata Szymaszkiewicz
Agata Szymaszkiewicz
JFJakub Fichna
Jakub Fichna
Marta ZielinskaMarta Zielinska
Marta Zielinska

1 April 2023 in Life Sciences
Verified
Journal Article
Open access
WMWeronika Machelak
Weronika Machelak
ASAdrian Szczepaniak
Adrian Szczepaniak
DJDamian Jacenik
Damian Jacenik
Marta ZielinskaMarta Zielinska
Marta Zielinska
GDF11 (Growth differentiation factor 11) is a newly discovered member of family of transforming growth factors-β. Its crucial role was confirmed in physiology, i.e. embryogenesis due to its involvement in bone formation, skeletogenesis and it is essential to stating skeletal pattern. GDF11 is described as a rejuvenating and anti-aging molecule, that could even restore functions. Beside embryogenesis, GDF11 participates in the process of inflammation and carcinogenesis. An anti-inflammatory effect of GDF11 was found in experimental colitis, psoriasis and arthritis. Current data regarding liver fibrosis and renal injury indicate that GDF11 may act as pro-inflammatory agent. In this review, we describe its involvement in regulation of acute and chronic inflammatory disorders.

12 June 2015 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Closed access
Marta ZielinskaMarta Zielinska
Marta Zielinska
AWAndrzej Wasilewski
Andrzej Wasilewski
JFJakub Fichna
Jakub Fichna
Constipation-predominant irritable bowel syndrome (IBS-C) is a common functional gastrointestinal (GI) disorder characterized by recurrent abdominal pain and prolonged GI transit. The pathogenesis of IBS-C has still not been established; therefore, drugs currently in use in IBS-C act mainly symptomatically, whereas novel pharmacological targets are urgently needed. Tenapanor is a potent inhibitor of Na(+)/H(+) exchanger 3 [NHE3], localized in the apical membrane of intestinal epithelial cells. NHE3 participates in the uptake of sodium ions and water from the intestinal lumen. In this review, the authors discuss pharmacodynamics and pharmacokinetics of tenapanor, focusing on animal models and in vitro studies. They also summarize clinical trials on tenapanor's safety and efficacy in view of its potential role in IBS-C therapy. Tenapanor possesses an excellent preclinical safety profile and, as of now, there are no serious concerns about its side effects. The non-systemic action of tenapanor constitutes a significant advantage, as it minimizes possible adverse effects or drug-drug interactions. However, Phase III clinical trials are still needed to confirm results obtained in earlier phases and optimize the dose-response for tenapanor, whereas limiting diarrhea, its major adverse effect.

30 January 2020 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Open access
PDF file
ASAgata Szymaszkiewicz
Agata Szymaszkiewicz
JWJakub Włodarczyk
Jakub Włodarczyk
AWAndrzej Wasilewski
Andrzej Wasilewski
Vincenzo Di MarzoVincenzo Di Marzo
Vincenzo Di Marzo
MSMartin Storr
Martin Storr
Marta ZielinskaMarta Zielinska
Marta Zielinska
TRPV1 are involved in the control of the gastrointestinal (GI) functions and pain sensation. Their activation induces pain but it is followed by desensitization, which in turn causes analgesia. The studies from the last two decades indicate that TRPV1 are involved in visceral hypersensitivity in the GI tract and pathogenesis of irritable bowel syndrome (IBS). Therefore, the aim of this study is to assess the action of fast desensitizing agonist of TRPV1, palvanil (N-palmitoyl-vanillamine), in the murine GI tract and on nociception to evaluate its potential application in the therapy of IBS. The effect of palvanil on smooth muscle contractility was evaluated using organ baths. The impact of palvanil on intestinal secretion was assessed in Ussing chambers. In vivo, the action of palvanil (0.1–1 mg/kg) was assessed in whole GI transit, fecal pellet output, and colonic bead expulsion tests. The antinociceptive potency of palvanil was tested in the mustard oil-induced pain test. Palvanil inhibited colonic contractions (evoked by electrical field stimulation, EFS) and decreased the ion transport in the colon stimulated with forskolin. It did not affect secretion in experiments with veratridine. In vivo, palvanil prolonged whole GI transit at all doses tested. At the lower dose tested, it accelerated colonic motility during first 60 min following injection. By contrast, at the dose of 1 mg/kg, colonic motility was inhibited. Palvanil induced antinociceptive action at all tested doses in mustard oil-induced pain test. TRPV1 fast-desensitizing compounds, i.e., palvanil, may be promising agents in the therapy of IBS since it modulates intestinal motility and reduces visceral pain.

14 October 2020 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
AFAdam Fabisiak
Adam Fabisiak
NFNatalia Fabisiak
Natalia Fabisiak
AMAnna Mokrowiecka
Anna Mokrowiecka
EMEwa Malecka‐Panas
Ewa Malecka‐Panas
Damian JacenikDamian Jacenik
Damian Jacenik
JFJakub Fichna
Jakub Fichna